Crynodebau o Gyfarfodydd
O. McCarthy, O. Moser, M.L. Eckstein, R. Deere, J. Pitt, S.C. Bain, J. Hayes, D.M. Williams, R.M. Bracken. Glycaemic impact of pre-and post exercise insulin aspart adjustments in individuals with type 1 diabetes treated with insulin degludec: a cross over randomised trial. 55th EASD Annual Meeting, 2019.
R.L. Thomas, W.Y. Cheung, J. Rafferty, S. Luzio, D.R. Owens. Causes of non-attendance at the diabetic eye screening service in Wales, UK: a retrospective population analysis. 55th EASD Annual Meeting, 2019.
R. Churm, L. Cranny, M. Salih, S,L, Prior, R.L. Thomas, S. Banerjee, D.R. Owens. Evaluation of fenofibrate action in diabetic retinopathy using a novel retinal triple culture model. 55th EASD Annual Meeting, 2019.
O. Moser, J. Rafferty, M.L. Eckstein, O. McCarthy, R.M. Bracken, H. Sourij, S.C. Bain, R.L.Thomas. Number of preceding episodes of severe hypoglycaemia determine subsequent acute death in people with type 1 diabetes: a retrospective cohort study. 55th EASD Annual Meeting, 2019.
S.C. Bain. The PIONEER journey: from concept to successful oral peptide delivery. 55th EASD Annual Meeting, 2019.
L.A.Leiter, S.C. Bain, D.L. Bhatt, J.B. Buse, C.D. Mazer, R. Pratley, S. Lindberg, S. Rasmussen, H. Vrazic, S. Verma. Liraglutide and semaglutide improve cardiovascular and renal outcomes across baseline BP categories: analysis of LEADER and SUSTAIN 6. 55th EASD Annual Meeting, 2019.
S.C. Bain, C.V. Desouza, T. Gondolf, T. Hansen, I. Holst, R.R. Rea, J. Seufert. The effect of once-weekly semaglutide on MACE, blood pressure and lipids by race and ethnicity: a SUSTAIN 6 post hoc analysis. 55th EASD Annual Meeting, 2019.
B. Zinman, S. Verma, S.C. Bain, J.B. Honoré, J. Mann, M.A. Nauck, R. Pratley, S. Rasmussen, M. Sejersten Ripa, J.B. Buse. Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials. 55th EASD Annual Meeting, 2019.
V. Perkovic, S.C. Bain, G. Bakris, J.B. Buse, T. Gondolf, T. Idorn, N. Lausvig, K. Mahaffey, S.P. Marso, M.A. Nauck, R. Pratley, P. Rossing, B. Zinman, J. Mann. Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER. 55th EASD Annual Meeting, 2019.
S. Verma, S.C. Bain, D.L. Bhatt, L.A. Leiter, C.D. Mazer, D.K. McGuire, R. Pratley, B. Zinman, S. Lindberg, S. Rasmussen, H. Vrazic, J.B. Buse. Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. 55th EASD Annual Meeting, 2019.